Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

105.20EUR
29 May 2017
Change (% chg)

-- (--)
Prev Close
€105.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
407,367
52-wk High
€115.20
52-wk Low
€82.00

Latest Key Developments (Source: Significant Developments)

Ablynx to receive 15 million euros milestone payment
Monday, 22 May 2017 01:00am EDT 

May 22 (Reuters) - ABLYNX NV ::NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT.ABLYNX ANNOUNCED THAT IT HAS COMPLETED PREPARATION OF A PRE-CLINICAL PACKAGE FOR A NOVEL NANOBODY® (ALX-1141) IN OSTEOARTHRITIS.AS PART OF ONGOING COLLABORATION BETWEEN ABLYNX AND MERCK KGAA <<>>, MERCK HAS ACCEPTED PRE-CLINICAL PACKAGE AND THIS HAS TRIGGERED A EUR 15 MILLION MILESTONE PAYMENT TO ABLYNX.MERCK IS NOW RESPONSIBLE FOR FURTHER CLINICAL DEVELOPMENT OF MOLECULE.  Full Article

Merck KGaA's Pergoveris fertility pen gets EU approval
Wednesday, 10 May 2017 07:22am EDT 

May 10 (Reuters) - Merck KGaA :Says European Commission grants approval for Merck’s new Pergoveris pen for fertility treatment.  Full Article

U.S. FDA grants accelerated approval to Avelumab for Urothelial Carcinoma
Tuesday, 9 May 2017 12:22pm EDT 

May 9 (Reuters) - U.S. FDA::U.S. Food and Drug Administration grants accelerated approval to avelumab for urothelial carcinoma.  Full Article

Merck KGaA acquires Grzybowski Scientific Inventions
Tuesday, 9 May 2017 08:05am EDT 

May 9 (Reuters) - MERCK KGAA ::ACQUIRES GRZYBOWSKI SCIENTIFIC INVENTIONS TO EXPAND CHEMICAL SYNTHESIS OFFERING.FINANCIAL DETAILS OF THE TRANSACTION WERE NOT DISCLOSED.  Full Article

FDA approves treatment for metastatic merkel cell carcinoma
Thursday, 23 Mar 2017 02:28pm EDT 

U.S. FDA: Granted accelerated approval to Bavencio for treatment of adults, pediatric patients 12 years and older with metastatic merkel cell carcinoma .Further clinical trials are required to confirm Bavencio’s clinical benefit.  Full Article

Merck KGaA announces release of two fertility technologies products
Friday, 10 Mar 2017 05:13am EST 

Merck Kgaa :release of 2 fertility technologies products for improved efficiency in assisted reproductive treatment lab, eevatest 3.0, geri humidified incubation.  Full Article

Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on BGB-283
Thursday, 2 Mar 2017 09:00am EST 

Beigene Ltd :Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on continuation option to develop, commercialize BGB-283 outside China.  Full Article

Merck says NICE expands a positive recommendation for Erbitux
Thursday, 2 Mar 2017 02:04am EST 

Merck KGaA :Says NICE expands positive recommendation for Erbitux as first-line treatment for RAS Wild-type mCRC.  Full Article

Pfizer sees 2017 Prevnar sales flat to slightly down
Tuesday, 31 Jan 2017 11:42am EST 

Pfizer Inc : Pfizer CEO says M&A focus on opportunities that contribute immediate or near-term revenue growth . Pfizer sees avelumab as core asset in immuno-oncology franchise with 30 ongoing trials . Pfizer CEO says looks forward to working with new Trump administration in 2017 . Pfizer sees 2017 Prevnar sales flat to slightly down .Pfizer CEO says not changing philosophy on drug pricing or when company takes increases.  Full Article

Merck Kgaa, Darmstadt, Germany, Palantir launch new healthcare partnership
Thursday, 12 Jan 2017 05:00pm EST 

Merck Kgaa : Merck KGAA - Merck KGAA, Darmstadt, Germany, and Palantir launch new healthcare acceleration partnership . Merck KGAA - financial details were not disclosed . Merck KGAA - initially Merck KGAA, Darmstadt, Germany, will apply Palantir's technology to cancer treatment and patient services .Merck KGAA - ultimately Merck KGAA, Darmstadt, Germany, plans to deploy Palantir's technology across all three of company's business sectors.  Full Article

More From Around the Web

Photo

Merck KGaA TV crystals sales decline raises stakes for cancer drug

FRANKFURT Merck KGaA's sales of liquid crystals used in flat-screen TVs are now expected to decline this year, making the German company more reliant on its new cancer immunotherapy drug to fuel growth.